A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
Wednesday, September 18, 2024, CLEVELAND: A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare ...
Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in ...
A repurposed cancer drug eases the frequent nosebleeds and other symptoms of a hereditary disease of the blood vessels 1. There is no approved therapy specifically for hereditary haemorrhagic ...
A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results